Organic |
Dextran |
GM-CSF, G-CSF.59
|
Chemical co-precipitation; weak electrolyte; ester bond.125
|
Easy modification; biocompatibility and biodegradability; enhancement of MHC I antigen presentation by DCs.126
|
PLGA |
IL-2,60 IL-18,66,127 IFN-α,58 TNF,127–129 IL-12,127,130 GM-CSF,128 IFN-γ.131
|
Emulsification-diffusion; solvent evaporation; nanoprecipitation methods.132,133
|
Biocompatibility; biodegradability. |
Chitosan |
GM-CSF,59 IL-12,134 IL-15,64 IL-21.65
|
Ionotropic gelation; microemulsion; emulsification solvent diffusion; polyelectrolyte complex formation. |
Hydrophily; stability; biodegradability. |
Liposome |
IL-2,60,135 TGF-β,60 IL-12,136,137 TNF-α.61
|
Reverse phase evaporation; thin film hydration; ultrasonic dispersion. |
Easy modification; hydrophily; reducing drug toxicity; stability.138,139
|
Inorganic |
Gold Nanoparticles |
IL-12,137 TNF,62,140,141 IFN.142
|
Galvanic replacement reaction; liquid phase reduction method; the use of dendrimers.143
|
Optical and electronic features; easy modification.144
|
Silicon |
GM-CSF,145 IFN-tau.146
|
Gas phase synthesis; supercritical fluid method; solid state method; liquid phase reduction method. |
Biocompatibility; hypotoxicity; large capacity; photoluminescence.147
|
Magnetic Nanoparticles |
TNF-α,141,148 IFN-γ,149 IFN-α2b,63 EGFR.67
|
Wet precipitation; co-precipitation; reverse micelle mechanism; thermal decomposition and reduction; liquid phase reduction. |
Directional migration; controllability of release; biocompatibility. |